Literature DB >> 16870790

AG205, a novel agent directed against FabK of Streptococcus pneumoniae.

Sho Takahata1, Maiko Iida, Yumi Osaki, Jun Saito, Hideo Kitagawa, Tomohiro Ozawa, Takuji Yoshida, Shigeru Hoshiko.   

Abstract

AG205 was identified from high-throughput screening as a potent inhibitor of FabK, the enoyl-ACP reductase in Streptococcus pneumoniae. Specific inhibition of lipid biosynthesis in a macromolecular biosynthesis assay and identification of an Ala141Ser substitution in FabK from spontaneous AG205-resistant mutants indicated that AG205 exerts antibacterial activity against S. pneumoniae through the specific inhibition of FabK.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16870790      PMCID： PMC1538662          DOI： 10.1128/AAC.00270-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  A triclosan-resistant bacterial enzyme.

Authors:  R J Heath; C O Rock
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

2.  Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis.

Authors:  R J Heath; Y T Yu; M A Shapiro; E Olson; C O Rock
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

3.  Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).

Authors:  Hedia Marrakchi; Walter E Dewolf; Chad Quinn; Joshua West; Brian J Polizzi; Chi Y So; David J Holmes; Shannon L Reed; Richard J Heath; David J Payne; Charles O Rock; Nicola G Wallis
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

4.  Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus.

Authors:  C Slater-Radosti; G Van Aller; R Greenwood; R Nicholas; P M Keller; W E DeWolf; F Fan; D J Payne; D D Jaworski
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

Review 5.  Lipid biosynthesis as a target for antibacterial agents.

Authors:  R J Heath; S W White; C O Rock
Journal:  Prog Lipid Res       Date:  2001-11       Impact factor: 16.195

6.  Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

Authors:  M A Seefeld; W H Miller; K A Newlander; W J Burgess; D J Payne; S F Rittenhouse; T D Moore; W E DeWolf; P M Keller; X Qiu; C A Janson; K Vaidya; A P Fosberry; M G Smyth; D D Jaworski; C Slater-Radosti; W F Huffman
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

7.  Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.

Authors:  R J Heath; J Li; G E Roland; C O Rock
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

8.  1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Authors:  D A Heerding; G Chan; W E DeWolf; A P Fosberry; C A Janson; D D Jaworski; E McManus; W H Miller; T D Moore; D J Payne; X Qiu; S F Rittenhouse; C Slater-Radosti; W Smith; D T Takata; K S Vaidya; C C Yuan; W F Huffman
Journal:  Bioorg Med Chem Lett       Date:  2001-08-20       Impact factor: 2.823

9.  Discovery of a novel and potent class of FabI-directed antibacterial agents.

Authors:  David J Payne; William H Miller; Valerie Berry; John Brosky; Walter J Burgess; Emile Chen; Walter E DeWolf; Andrew P Fosberry; Rebecca Greenwood; Martha S Head; Dirk A Heerding; Cheryl A Janson; Deborah D Jaworski; Paul M Keller; Peter J Manley; Terrance D Moore; Kenneth A Newlander; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Courtney Slater-Radosti; Kevin L Salyers; Mark A Seefeld; Martin G Smyth; Dennis T Takata; Irene N Uzinskas; Kalindi Vaidya; Nicola G Wallis; Scott B Winram; Catherine C K Yuan; William F Huffman
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Authors:  Mark A Seefeld; William H Miller; Kenneth A Newlander; Walter J Burgess; Walter E DeWolf; Patricia A Elkins; Martha S Head; Dalia R Jakas; Cheryl A Janson; Paul M Keller; Peter J Manley; Terrance D Moore; David J Payne; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Irene N Uzinskas; Nicola G Wallis; William F Huffman
Journal:  J Med Chem       Date:  2003-04-24       Impact factor: 7.446
View more
  10 in total

Review 1.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis.

Authors:  Kirk E Hevener; Shahila Mehboob; Teuta Boci; Kent Truong; Bernard D Santarsiero; Michael E Johnson
Journal:  Protein Expr Purif       Date:  2012-07-20       Impact factor: 1.650

3.  Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.

Authors:  Qingye Zhang; Chan Yu; Jun Min; Yan Wang; Jin He; Ziniu Yu
Journal:  J Mol Model       Date:  2010-09-23       Impact factor: 1.810

Review 4.  Bacterial Enoyl-Reductases: The Ever-Growing List of Fabs, Their Mechanisms and Inhibition.

Authors:  Fernanda S M Hopf; Candida D Roth; Eduardo V de Souza; Luiza Galina; Alexia M Czeczot; Pablo Machado; Luiz A Basso; Cristiano V Bizarro
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

5.  Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor.

Authors:  Jun Saito; Mototsugu Yamada; Takashi Watanabe; Maiko Iida; Hideo Kitagawa; Sho Takahata; Tomohiro Ozawa; Yasuo Takeuchi; Fukuichi Ohsawa
Journal:  Protein Sci       Date:  2008-02-27       Impact factor: 6.725

Review 6.  Diversity in enoyl-acyl carrier protein reductases.

Authors:  R P Massengo-Tiassé; J E Cronan
Journal:  Cell Mol Life Sci       Date:  2009-05       Impact factor: 9.261

7.  Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity.

Authors:  Jesse A Jones; Allan M Prior; Ravi K R Marreddy; Rebecca D Wahrmund; Julian G Hurdle; Dianqing Sun; Kirk E Hevener
Journal:  ACS Chem Biol       Date:  2019-06-26       Impact factor: 5.100

8.  Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents.

Authors:  Sidhartha S Kar; Varadaraj Bhat G; Praveen Pn Rao; Vishnu P Shenoy; Indira Bairy; G Gautham Shenoy
Journal:  Drug Des Devel Ther       Date:  2016-07-18       Impact factor: 4.162

9.  The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection.

Authors:  Ravi K R Marreddy; Xiaoqian Wu; Madhab Sapkota; Allan M Prior; Jesse A Jones; Dianqing Sun; Kirk E Hevener; Julian G Hurdle
Journal:  ACS Infect Dis       Date:  2018-12-13       Impact factor: 5.084

10.  The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance.

Authors:  Lei Zhu; Hongkai Bi; Jincheng Ma; Zhe Hu; Wenbin Zhang; John E Cronan; Haihong Wang
Journal:  MBio       Date:  2013-10-01       Impact factor: 7.867
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.